Nivolumab trials for Lung cancer

All Nivolumab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Nivolumab for Lung cancer

• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
  NCT06764771 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 322 locations
• A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
  NCT07541170 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
  NCT04991025 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
  NCT07195695 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 202 locations
• Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
  NCT05317858 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 14 locations
• BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
  NCT04933903 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
  NCT05681780 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
  NCT06265285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
  NCT06364917 · Phase: Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 1 location
• Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
  NCT06495125 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
  NCT06731270 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
  NCT06532149 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
  NCT07355205 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
  NCT05715229 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
  NCT06554613 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
  NCT05234307 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
  NCT07223424 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
  NCT05098210 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
  NCT07394062 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Repositioning Immunotherapy in VetArans With Lung Cancer
  NCT06275360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
  NCT05501665 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
  NCT05267626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 244 locations
• Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
  NCT06908993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
  NCT07246863 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Using ctDNA to Determine Therapies for Lung Cancer
  NCT04966663 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Nivolumab for Lung cancer?

29 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.